Oncotrack is a non-invasive screening test which can identify genetic alterations, interpret, assess and monitor various forms of cancer
MedGenome, a genomics-based research and diagnostics company has launched Oncotrack. The liquid biopsy-based Oncotrack is a non-invasive screening test which can identify genetic alterations, interpret, assess and treat various forms of cancer.
The test developed entirely by MedGenome, is validated in India and verified from samples of cancer patients from across the country. The test screens the samples by analysing cell-free DNA that is isolated from the patients’ blood. Using high-end sequencing technology, the screening process identifies specific gene mutations that are linked with melanoma, lung and colon cancers. The test facilitates detection of mutation where there is difficulty of obtaining biopsy or in an event of damaged biopsy material and non-availability of tissue biopsy. This offers oncologists the power to look for actionable alterations in a patient’s treatment, management, without having to do an invasive biopsy or where biopsy is not an option.
The test has been validated in a scientific study, in academic collaboration with Tata Memorial Hospital — Dr Kumar Prabhash, Medical Oncologist and Dr Amit Dutt, Principal Investigator (Scientist F) at ACTREC, Tata Memorial Centre.
Dr Prabhash said, “As care gets more personalised, doctors will be equipped to make correct diagnosis, prognosis and prediction of diseases. Cell free tumour DNA (ctDNA) analysis will help in avoiding repeat biopsies of difficult to get tumours and also in monitoring the overall response to treatment on real time basis.”